Mechanism of Action of Hormones That Act at the Cell Surface

Williams Textbook of Endocrinology, Twelfth Edition

Volumn , Issue , 2011, Pages 62-82

  Spiegel, Allen M ^a   Carter Su, Christin ^b,c   Taylor, Simeon I ^d   Kulkarni, Rohit N ^e,f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e JOSLIN DIABETES CENTER   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85170154925     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-0324-5.00005-5     Document Type: Chapter

References (163)

1. JE Fradkin, RC Eastman, MA Lesniak, et al. (1989) Specificity spillover at the hormone receptor—exploring its role in human disease. N Engl J Med 320 640-645.
2. T Hunter (1998) The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos Trans R Soc Lond B Biol Sci 353 583-605.
3. SK Hanks and T Hunter (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 9 576-596.
4. H Ushiro and S Cohen (1980) Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J Biol Chem 255 8363-8365.
5. A Ullrich, L Coussens, JS Hayflick, et al. (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309 418-425.
6. A Ullrich, A Gray, AW Tam, et al. (1986) Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5 2503-2512.
7. A Weiss and J Schlessinger (1998) Switching signals on or off by receptor dimerization. Cell 94 277-280.
8. B Westermark, L Claesson-Welsh and CH Heldin (1989) Structural and functional aspects of the receptors for platelet-derived growth factor. Prog Growth Factor Res 1 253-266.
9. CH Heldin, A Ostman and L Ronnstrand (1998) Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1378 F79-F113.
10. BC Cunningham, M Ultsch, AM De Vos, et al. (1991) Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254 821-825.
11. AM de Vos, M Ultsch and AA Kossiakoff (1992) Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255 306-312.
12. JA Wells (1996) Binding in the growth hormone receptor complex. Proc Natl Acad Sci U S A 93 1-6.
13. C Wiesmann, G Fuh, HW Christinger, et al. (1997) Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91 695-704.
14. M Boni-Schnetzler, JB Rubin and PF Pilch (1986) Structural requirements for the transmembrane activation of the insulin receptor kinase. J Biol Chem 261 15281-15287.
15. M Boni-Schnetzler, W Scott, SM Waugh, et al. (1987) The insulin receptor: structural basis for high affinity ligand binding. J Biol Chem 262 8395-8401.
16. M Taouis, R Levy-Toledano, P Roach, et al. (1994) Structural basis by which a recessive mutation in the alpha-subunit of the insulin receptor affects insulin binding. J Biol Chem 269 14912-14918.
17. P De Meyts (1994) The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia 37 S135-S148.
18. SR Hubbard, L Wei, L Ellis, et al. (1994) Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372 746-754.
19. SR Hubbard (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16 5572-5581.
20. SR Hubbard, M Mohammadi and J Schlessinger (1998) Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 273 11987-11990.
21. R Herrera and OM Rosen (1987) Regulation of the protein kinase activity of the human insulin receptor. J Recept Res 7 405-415.
22. HE Tornqvist and J Avruch (1988) Relationship of site-specific beta subunit tyrosine autophosphorylation to insulin activation of the insulin receptor (tyrosine) protein kinase activity. J Biol Chem 263 4593-4601.
23. A Ullrich and J Schlessinger (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61 202-203.
24. WM Kavanaugh and LT Williams (1994) An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. Science 266 1862-1865.
25. P Blaikie, D Immanuel, J Wu, et al. (1994) A region in Shc distinct from the SH2 domain can bind tyrosine-phosphorylated growth factor receptors. J Biol Chem 269 32031-32034.
26. TA Gustafson, W He, A Craparo, et al. (1995) Phosphotyrosine-dependent interaction of Shc and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain. Mol Cell Biol 15 2500-2508.
27. D Anderson, CA Koch, L Grey, et al. (1990) Binding of SH2 domains of phospholipase Cg 1, GAP, and Src to activated growth factor receptors. Science 250 979-982.
28. N Perrotti, D Accili, B Marcus-Samuels, et al. (1987) Insulin stimulates phosphorylation of a 120-kDa glycoprotein substrate (pp120) for the receptor-associated protein kinase in intact H-35 hepatoma cells. Proc Natl Acad Sci U S A 84 3137-3140.
29. SM Najjar, N Philippe, Y Suzuki, et al. (1995) Insulin-stimulated phosphorylation of recombinant pp120/HA4, an endogenous substrate of the insulin receptor tyrosine kinase. Biochemistry 34 9341-9349.
30. H Kouhara, YR Hadari, T Spivak-Kroizman, et al. (1997) A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell 89 692-693.
31. MF White and L Yenush (1998) The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Curr Top Microbiol Immunol 228 178-179.
32. JN Winnay, JC Brüning, DJ Burks, et al. (2000) Gab-1-mediated IGF-1 signaling in IRS-1-deficient 3T3 fibroblasts. J Biol Chem 275 10545-10550.
33. A Janez, DS Worrall, T Imamura, et al. (2000) The osmotic shock-induced glucose transport pathway in 3T3-L1 adipocytes is mediated by gab-1 and requires Gab-1-associated phosphatidylinositol 3-kinase activity for full activation. J Biol Chem 275 26870-26876.
34. XJ Sun, P Rothenberg, CR Kahn, et al. (1991) Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352 73-77.
35. XJ Sun, LM Wang, Y Zhang, et al. (1995) Role of IRS-2 in insulin and cytokine signaling. Nature 377 173-177.
36. BE Lavan, WS Lane and GE Lienhard (1997) The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J Biol Chem 272 11439-11443.
37. S Sciacchitano and SI Taylor (1997) Cloning, tissue expression, and chromosomal localization of the mouse IRS-3 gene. Endocrinology 138 4931-4940.
38. MJ Quon, H Chen, BL Ing, et al. (1995) Roles of 1-phosphatidylinositol 3-kinase and ras in regulating translocation of GLUT4 in transfected rat adipose cells. Mol Cell Biol 15 5403-5411.
39. AD Kohn, SA Summers, MJ Birnbaum, et al. (1996) Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 271 31372-31378.
40. LN Cong, H Chen, Y Li, et al. (1997) Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells. Mol Endocrinol 11 1881-1890.
41. ML Standaert, L Galloway, P Karnam, et al. (1997) Protein kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat adipocytes. Potential role in glucose transport. J Biol Chem 272 30075-30082.
42. T Kitamura, W Ogawa, H Sakaue, et al. (1998) Requirement for activation of the serine-threonine kinase Akt (protein kinase B) in insulin stimulation of protein synthesis but not of glucose transport. Mol Cell Biol 18 3708-3717.
43. DR Alessi, M Deak, A Casamayor, et al. (1997) 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 7 776-779.
44. DR Alessi and CP Downes (1998) The role of PI 3-kinase in insulin action. Biochim Biophys Acta 1436 151-154.
45. B Cheatham, CJ Vlahos, L Cheatham, et al. (1994) Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 14 4902-4911.
46. R Watson, S Shigematsu, S Chiang, et al. (2001) Lipid raft microdomain compartmentalization of TC10 is required for insulin signaling and GLUT4 translocation. J Cell Biol 154 829-840.
47. CA Baumann, V Ribon, M Kanzaki, et al. (2000) CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 407 202-207.
48. SH Chiang, CA Baumann, M Kanzaki, et al. (2001) Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 410 944-948.
49. EJ Lowenstein, RJ Daly, AG Batzer, et al. (1992) The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70 431-432.
50. GJ Pronk, J McGlade, G Pelicci, et al. (1993) Insulin-induced phosphorylation of the 46- and 52-kDa Shc proteins. J Biol Chem 268 5748-5753.
51. EY Skolnik, CH Lee, A Batzer, et al. (1993) The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J 12 1929-1936.
52. N Li, A Batzer, R Daly, et al. (1993) Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 363 85-88.
53. Y Yarden, JA Escobedo, WJ Kuang, et al. (1986) Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 323 226-232.
54. SF Clark, S Martin, AJ Carozzi, et al. (1998) Intracellular localization of phosphatidylinositide 3-kinase and insulin receptor substrate-1 in adipocytes: potential involvement of a membrane skeleton. J Cell Biol 140 1211-1225.
55. C Belham, S Wu and J Avruch (1999) Intracellular signalling: PDK1-a kinase at the hub of things. Curr Biol 9 R93-R96.
56. J Avruch, A Khokhlatchev, JM Kyriakis, et al. (2001) Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 56 127-155.
57. RN Kulkarni, JC Brüning, JN Winnay, et al. (1999) Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96 329-339.
58. DJ Withers, JS Gutierrez, H Towery, et al. (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391 900-904.
59. A Assmann, C Hinault and RN Kulkarni (2009) Growth factor control of pancreatic islet regeneration and function. Pediatr Diabetes 10 14-32.
60. JC Brüning, D Gautam, DJ Burks, et al. (2000) Role of brain insulin receptor in control of body weight and reproduction. Science 289 2122-2125.
61. SJ Fisher, JC Brüning, S Lannon, et al. (2005) Insulin signaling in the central nervous system is critical for the normal sympathoadrenal response to hypoglycemia. Diabetes 54 1447-1451.
62. A Taguchi, LM Wartschow and MF White (2007) Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 317 369-372.
63. C Bouche, X Lopez, A Fleischmann, et al. (2010) Insulin enhances glucose-stimulated insulin secretion in healthy humans. Proc Natl Acad Sci U S A 107 4770-4775.
64. CR Kahn, JC Brüning, MD Michael, et al. (2000) Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes mellitus. J Pediatr Endocrinol Metab 13(suppl 6), 1377-1384.
65. JL Carpentier (1994) Insulin receptor internalization: molecular mechanisms and physiopathological implications. Diabetologia 37 S117-S124.
66. JL Carpentier, I Hamer, A Gilbert, et al. (1996) Molecular and cellular mechanisms governing the ligand-specific and non-specific steps of insulin receptor internalization. Z Gastroenterol 34 73-75.
67. JS Flier, KL Minaker, L Landsberg, et al. (1982) Impaired in vivo insulin clearance in patients with severe target-cell resistance to insulin. Diabetes 31 132-135.
68. M Elchebly, P Payette, E Michaliszyn, et al. (1999) Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283 1544-1548.
69. LD Klaman, O Boss, OD Peroni, et al. (2000) Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 20 5479-5489.
70. GS Hotamisligil, P Peraldi, A Budavari, et al. (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 271 665-668.
71. K De Fea and RA Roth (1997) Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J Biol Chem 272 31400-31406.
72. J Li, K DeFea and RA Roth (1999) Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway. J Biol Chem 274 9351-9356.
73. V Aguirre, T Uchida, L Yenush, et al. (2000) The c-Jun NH 2 terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275 9047-9054.
74. L Rui, V Aguirre, JK Kim, et al. (2001) Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 107 181-189.
75. SI Taylor (1992) Lilly lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 41 1473-1490.
76. F Carlomagno, G Salvatore, AM Cirafici, et al. (1997) The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 57 391-395.
77. LM Mulligan, JB Kwok, CS Healey, et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 458-460.
78. M Santoro, F Carlomagno, A Romano, et al. (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267 381-383.
79. DB Drachman (1994) Myasthenia gravis. N Engl J Med 330 1797-1810.
80. CR Kahn, JS Flier, RS Bar, et al. (1976) The syndromes of insulin resistance and acanthosis nigricans: insulin-receptor disorders in man. N Engl J Med 294 739-745.
81. JS Flier, CR Kahn, J Roth, et al. (1975) Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science 190 63-65.
82. SI Taylor and B Marcus-Samuels (1984) Anti-receptor antibodies mimic the effect of insulin to down-regulate insulin receptors in cultured human lymphoblastoid (IM-9) cells. J Clin Endocrinol Metab 58 182-186.
83. AP Weetman (2000) Graves’ disease. N Engl J Med 343 1236-1248.
84. JS Flier, RS Bar, M Muggeo, et al. (1978) The evolving clinical course of patients with insulin receptor autoantibodies: spontaneous remission or receptor proliferation with hypoglycemia. J Clin Endocrinol Metab 47 985-995.
85. SI Taylor, G Grunberger, B Marcus-Samuels, et al. (1982) Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med 307 1422-1426.
86. Y Shi and J Massague (2003) Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113 685-700.
87. RN Kulkarni, ZL Wang, RM Wang, et al. (1997) Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest 100 2729-2736.
88. SD Covey, RD Wideman, C McDonald, et al. (2006) The pancreatic beta cell is a key site for mediating the effects of leptin on glucose homeostasis. Cell Metab 4 291-302.
89. T Morioka, E Asilmaz, J Hu, et al. (2007) Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. J Clin Invest 117 2860-2868.
90. S Amselem, P Duquesnoy, O Attree, et al. (1989) Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med 321 989-995.
91. K Clement, C Vaisse, N Lahlou, et al. (1998) A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392 398-401.
92. RL Bogorad, C Courtillot, C Mestayer, et al. (2008) Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci U S A 105 14533-14538.
93. LS Smit, DJ Meyer, LS Argetsinger, et al. (1999) Molecular events in growth hormone-receptor interaction and signaling. JS Kostyo, HM Goodman,(Eds) Handbook of Physiology New York, NY: Oxford University Press 445-480.
94. J Bravo and JK Heath (2000) Receptor recognition by gp130 cytokines. EMBO J 19 2399-2411.
95. CJ Auernhammer and S Melmed (2000) Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev 21 313-345.
96. PD Lambert, KD Anderson, MW Sleeman, et al. (2001) Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci U S A 98 4652-4657.
97. SM Opal and VA DePalo (2000) Anti-inflammatory cytokines. Chest 117 1162-1172.
98. MH Heim (1999) The JAK-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res 19 75-120.
99. GS Campbell, LS Argetsinger, JN Ihle, et al. (1994) Activation of JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants. Proc Natl Acad Sci U S A 91 5232-5236.
100. LS Argetsinger, GS Campbell, X Yang, et al. (1993) Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74 237-244.
101. RJ Brown, JJ Adams, RA Pelekanos, et al. (2005) Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 12 814-821.
102. P Saharinen and O Silvennoinen (2002) The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277 47954-47963.
103. M Noguchi, H Yi, HM Rosenblatt, et al. (1993) Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73 147-157.
104. E Parganas, D Wang, D Stravopodis, et al. (1998) JAK2 is essential for signaling through a variety of cytokine receptors. Cell 93 385-395.
105. JN Ihle, W Thierfelder, S Teglund, et al. (1998) Signaling by the cytokine receptor superfamily. Ann N Y Acad Sci 865 1-9.
106. N Stahl, TG Boulton, T Farruggella, et al. (1994) Association and activation of JAK-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 263 92-95.
107. E Stoecklin, M Wissler, D Schaetzle, et al. (1999) Interactions in the transcriptional regulation exerted by STAT5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol 69 195-204.
108. EM Kofoed, V Hwa, B Little, et al. (2003) Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 349 1139-1147.
109. V Hwa, B Little, P Adiyaman, et al. (2005) Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab 90 4260-4266.
110. EJ Baxter, LM Scott, PJ Campbell, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 1054-1061.
111. TS Lin, S Mahajan and DA Frank (2000) STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 19 2496-2504.
112. H Yasukawa, H Misawa, H Sakamoto, et al. (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 18 1309-1320.
113. JA Hansen, K Lindberg, DJ Hilton, et al. (1999) Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol Endocrinol 13 1832-1843.
114. PA Ram and DJ Waxman (1999) SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem 274 35553-35561.
115. SJ Frank and SY Fuchs (2008) Modulation of growth hormone receptor abundance and function: roles for the ubiquitin-proteasome system. Biochim Biophys Acta 784-794.
116. A Flores-Morales, CJ Greenhalgh, G Norstedt, et al. (2006) Negative regulation of growth hormone receptor signaling. Mol. Endocrinology 20 241-253.
117. Y Mao, PR Ling, TP Fitzgibbons, et al. (1999) Endotoxin-induced inhibition of growth hormone receptor signaling in rat liver in vivo. Endocrinology 140 5505-5515.
118. CV Clevenger and MV Medaglia (1994) The protein tyrosine kinase P59fyn is associated with prolactin (PRL) receptor and is activated by PRL stimulation of T-lymphocytes. Mol Endocrinol 8 674-681.
119. L Rui and C Carter-Su (1999) Identification of SH2-Bbeta as a potent cytoplasmic activator of the tyrosine kinase Janus kinase 2. Proc Natl Acad Sci U S A 96 7172-7177.
120. K Shuai and B Liu (2005) Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 5 593-605.
121. K Shuai (2006) Regulation of cytokine signaling pathways by PIAS proteins. Cell Res 16 196-202.
122. J Bockaert and JP Pin (1999) Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J 18 1723-1729.
123. EJ Neer (1995) Heterotrimeric G proteins: organizers of transmembrane signals. Cell 80 249-257.
124. WM Oldham and HE Hamm (2008) Heterotrimeric G protein activation by G-protein-coupled receptors. Nature Reviews/Molecular Cell Biology 9 60-71.
125. M Rodbell (1992) The role of GTP-binding proteins in signal transduction: from the sublimely simple to the conceptually complex. Curr Top Cell Regul 32 1-47.
126. RJ Lefkowitz (2004) Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol Sci 25 413-422.
127. CG Tate and GFX Schertler (2009) Engineering G protein-coupled receptors to facilitate their structure determination. Curr Opin Struct Biol 19 1-10.
128. T Muto, D Tsuchiya, K Morikawa and H Jingami (2007) Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc Natl Acad Sci 104 3759-3764.
129. QR Fan and WA Hendrickson (2005) Structure of the human follicle-stimulating hormone in complex with its receptor. Nature 433 269-277.
130. SRJ Hoare (2005) Mechanisms of peptide and nonpeptide ligand binding to class B G protein-coupled receptors. Drug Discovery Today 10 417-427.
131. J Wess (Ed.) (1999) Structure-Function Analysis of G Protein-Coupled Receptors New York: Wiley-Liss
132. T Yamashita, A Terakita and Y Shichida (2000) Distinct roles of the second and third cytoplasmic loops of bovine rhodopsin in G protein activation. J Biol Chem 275 34272-34279.
133. M Gershengorn and R Osman (2001) Insights into G protein-coupled receptor function using molecular models. Endocrinology 142 2-10.
134. W Soudijn, IV Wijngaarden and AP Ijzerman (2005) Structure-activity relationships of inverse agonists for G protein-coupled receptors. Medicinal Res Rev 25 398-426.
135. M Audet and M Bouvier (2008) Insights into signaling from the β 2-adrenergic receptor structure. Nat Chem Biol 4 397-403.
136. TE Herbert, S Moffett, JP Morello, et al. (1996) A peptide derived from a β2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271 16384-16392.
137. K Ray, BC Hauschild, PJ Steinbach, et al. (1999) Identification of the cysteine residues in the amino-terminal extracellular domain of the human Ca 2+ receptor critical for dimerization. J Biol Chem 274 27642-27650.
138. J-P Pin, J Kniazeff, J Liu, et al. (2005) Allosteric functioning of dimeric class C G protein-coupled receptors. FEBS J 272 2947-2955.
139. K Kaupmann, B Malitschek, V Schuler, et al. (1998) GABA-B receptor subtypes assemble into functional heteromeric complexes. Nature 396 683-687.
140. A Levoye, J Dam, MA Ayoub, et al. (2006) Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers. EMBO J 7 1094-1098.
141. RJ Lefkowitz and SK Shenoy (2005) Transduction of receptor signals by β-arrestins. Science 308 512-517.
142. JC Tu, B Xiao, JP Yuan, et al. (1998) Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron 21 717-726.
143. L McLatchie, N Fraser, M Main, et al. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-like receptor. Nature 393 333-339.
144. SC Hebert (2004) Orphan detectors of metabolism. Nature 429 143-145.
145. AM Spiegel and LS Weinstein (2004) Inherited diseases involving G proteins and G protein-coupled receptors. Ann Rev Med 55 27-39.
146. SB Seminara, S Messager, EE Chatzidaki, et al. (2003) The GPR54 gene as a regulator of puberty. N Engl J Med 349 1614-1627.
147. LW Cole, Y Sidis, CK Zhang, et al. (2008) Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonaotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. J Clin Endocrinol Metab 93 3551-3559.
148. LS Barak, RH Oakley, SA Laporte, et al. (2001) Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci U S A 98 93-98.
149. J Hu and AM Spiegel (2007) Structure and function of the human calcium-sensing receptor: insights from natural and engineered mutations and allosteric modulators. J Cellular Molecular Medicine 11 908-922.
150. J Van Sande, J Parma, M Tonacchera, et al. (1995) Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab 80 2577-2585.
151. JA Javitch, D Fu, G Liapakis and J Chen (1997) Constitutive activation of the β2-adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem 272 18546-18549.
152. BJ Feldman, SM Rosenthal, GA Vargas, et al. (2005) Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 352 1884-1890.
153. L Lin, J Faraco, R Li, et al. (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98 365-376.
154. IS Farooqi, JM Keough, GS Yeo, et al. (2003) Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348 1085-1095.
155. B Lanske, AC Karaplis, K Lee, et al. (1996) PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273 663-666.
156. AS Jobert, P Zhang, A Couvineau, et al. (1998) Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. J Clin Invest 102 34-40.
157. J Luo, W Zhou, X Zhou, et al. (2009) Regulation of bone formation and remodeling by G protein-coupled receptor 48. Development 136 2747-2756.
158. J Deng, S Lang, C Wylie and SR Hammes (2008) The Xenopus laevis isoform of a G protein-coupled receptor 3 (GPR3) is a constitutively active cell surface receptor that participates in maintaining meiotic arrest in X. laevis oocytes. Mol Endocrinol 22 1853-1865.
159. K Sangkuhl, A Schulz, H Rompler, et al. (2004) Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum Mol Gen 13 893-903.
160. C Castro-Fernandez, G Maya-Nunez and PM Conn (2005) Beyond the signal sequence: protein routing in health and disease. Endocr Rev 26 479-503.
161. L Monanelli, A Delbaere, C Di Carlo, et al. (2004) A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 89 1255-1258.
162. J Kazius, K Wurdinger, M van Iterson, et al. (2008) GPCR NaVa database: natural variants in human G-protein-coupled receptors. Human Mutation 29 39-44.
163. GW Dorn and SB Liggett (2009) Mechanisms of genetic effects of pharmacogenomic variation within the adrenergic receptor network in heart failure. Mol Pharm 76 466-480.